Inhalation Lenalidomide-Loaded Liposome for Bleomycin-Induced Pulmonary Fibrosis Improvement
AAPS PharmSciTech. 2023 Nov 16;24(8):235. doi: 10.1208/s12249-023-02690-w.ABSTRACTIdiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic interstitial lung disease with unclear etiology and increasing prevalence. Pulmonary administration can make the drug directly reach the lung lesion location and reduce systemic toxic and side effects. The effectiveness of lenalidomide (Len) liposomal lung delivery in idiopathic pulmonary fibrosis was investigated. Len liposomes (Len-Lip) were prepared from soybean lecithin, cholesterol (Chol), and medicine in different weight ratios by thin film hydration method. The Len-Lip were...
Source: AAPS PharmSciTech - November 16, 2023 Category: Drugs & Pharmacology Authors: Zhilin Luo Liyuan Ji Hongting Liu Yao Sun Conglu Zhao Xiang Xu Xiaoting Gu Xiaoyu Ai Cheng Yang Source Type: research
Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report
(Source: Annals of Hematology)
Source: Annals of Hematology - November 11, 2023 Category: Hematology Source Type: research
Cancers, Vol. 15, Pages 5338: Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study
Conclusions: The study reveals a progressive increase in the number of MM patients treated and rising pharmaceutical costs. Lenalidomide and daratumumab incurred the highest costs. The findings highlight MM treatment’s economic impact and the need to monitor prescription patterns and expenditures to optimize healthcare resources and decision making. Understanding these trends can guide resource allocation effectively. (Source: Cancers)
Source: Cancers - November 9, 2023 Category: Cancer & Oncology Authors: Gemma Garrido-Alejos Guillem Saborit-Canals Laura Guarga Thais de Pando Miriam Umbria Albert Oriol Anna Feliu Caridad Pontes Antonio Vallano Tags: Article Source Type: research
Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews
AbstractThe present study is an overview of systematic reviews focusing on adverse events of antimyeloma treatments. It provides a systematic description of adverse events as they are reported in the systematic reviews as well as a critical appraisal of included reviews. We conducted a comprehensive literature search in the most widely used electronic databases looking for systematic reviews that had an adverse event of an antimyeloma treatment intervention as primary outcome. Two independent reviewers conducted selection of included studies and data extraction on predesigned online forms and assessed study quality using A...
Source: Annals of Hematology - November 8, 2023 Category: Hematology Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Multiple myeloma (MM) remains incurable and follows a relapsing-remitting cycle.1,2 Despite significant advances in therapy, particularly the introduction of immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, patients with relapsed/refractory MM (RRMM) typically have poorer outcomes following each subsequent treatment.1-3 In newly diagnosed MM, lenalidomide now forms part of the standard of care as a component of triplet regimens or as maintenance therapy.3,4 This has resulted in a population of patients with MM who are refractory to lenalidomide early in their treatment due to remaining on lenalido...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 7, 2023 Category: Hematology Authors: Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, Meral Beksac, Thierry Facon, Sujith Dhanasiri, Shien Guo, Yutian Mu, Kevin Hong, Christian Gentili, Monica Galli, Munci Yagci, Alessandra Larocca, Paul Richardson, Katja Weisel Tags: Original Study Source Type: research
Minimal residual disease status is the prognostic determinant following high ‐dose treatment for patients with multiple myeloma
ConclusionsOur results indicate that being MRD − is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second-line setting, suggesting that these patients may requ ire a more intensive treatment approach. (Source: Cancer Medicine)
Source: Cancer Medicine - November 3, 2023 Category: Cancer & Oncology Authors: Hareth Nahi,
Gabriel Afram,
Katarina Uttervall,
Sandra Lockmer,
Love T ätting,
Gösta Gahrton,
Muhammad Kashif,
Evren Alici,
Olga Stromberg,
Monika Klimkowska,
Johan Lund Tags: RESEARCH ARTICLE Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema
We present a patient with SDRIFE secondary to lenalidomide, an immunomodulatory agent. This case highlights the importance of considering SDRIFE in the differential diagnosis of patients presenting with intertriginous erythema.PMID:37921816 | DOI:10.5070/D329461905 (Source: Dermatol Online J)
Source: Dermatol Online J - November 3, 2023 Category: Dermatology Authors: Riya T Patel Eugenie Y Quan Joshua D Eikenberg Douglas J Grider Mariana A Phillips Source Type: research
